MedTrace Logo

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2017-08-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AC-170 0.05%

1 drop in each eye at 3 separate times during a 21 day period

DRUG

AC-170 0.1%

1 drop in each eye at 3 separate times during a 21 day period

DRUG

AC-170 0.24%

1 drop in each eye at 3 separate times during a 21 day period

DRUG

AC-170 0%

1 drop in each eye at 3 separate times during a 21 day period

Sponsors & Collaborators

  • Aciex Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Gail L Torkildsen, MD · Andover Eye Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-06-30
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01332188 on ClinicalTrials.gov